Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic responseAmir Fathi, Yi‐Bin Chen, Hossein Sadrzadeh et al.|Blood|2012Cited by 123
Isocitrate dehydrogenase 1 and 2 mutations, 2‐hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemiaAndrew M. Brunner, Amir Fathi, Donna Neuberg et al.|Cancer|2018Cited by 33
Molecular alterations underlying eosinophilic and mast cell malignancies.Hossein Sadrzadeh, Amir Fathi, Omar Abdel‐Wahab|PubMed|2011Cited by 8
Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid LeukemiaAndrew M. Brunner, Amir Fathi, Donna Neuberg et al.|Blood|2015Cited by 6
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S. Wang, Ghayas C. Issa, James K. Mangan et al.|Blood|2026Cited by 0